This dilemma is most pronounced in the combination of POLEmut‐p53abn EC, in which the tumour exhibits both a favourable pathogenic mutation in the POLE exonuclease domain as well as unfavourable aberrant p53 IHC expression, such as illustrated in our case in Figure 2A,B. This evidence concerns the gene TP53 and neoplasm.